Posted On: 11/18/2015 9:37:53 PM
Post# of 30066
http://continentalaccessltd.com/amarantus-bio...17th-18th/
Amarantus Bioscience Holdings, Inc. (AMBS)
Developing therapeutic and diagnostic products for neurological disorders and orphan indications.
WE ARE PLEASED TO ANNOUNCE
AMARANTUS BIOSCIENCE HOLDINGS, INC.
AS A PRESENTING COMPANY AT THE MONACO GROWTH FORUM NOVEMBER 17th-18th
Amarantus Bioscience Holdings, Inc. (AMBS) was founded by a world-renewed molecular biologist and his Stanford University educated son to acquire and develop groundbreaking technologies in the biotechnology space. The management team has over 75 years of experience in the biotechnology sector in large pharmaceutical companies, small biotech companies, government and academic settings.
Amarantus Bioscience Holdings, Inc. (AMBS) will focus on developing unique technologies in the wound care/dermatology, neurology and ophthalmology sectors that address the critical unmet needs in each category. The technologies being developed all have clinical proof-of-concept and are being moved into mid-to-late stage clinical development on a path towards commercialization. The market opportunities in wound care/dermatology, neurology and ophthalmology represents $2B+, $4B+ and $2B+ respectively.
AMBS seeks to raise up to $30M US dollars to develop these assets through various stages of development.The funding can be focused on specific assets in special vehicles in order to participate in asset-centric valuation inflexion events. An acquisition of one or more of the assets by a larger pharmaceutical companies is the exit opportunity for institutional investors
AMBS’s objective is to develop these assets through further proof of concept in the next 12-24 months and divest the assets to larger companies in order to reinvest in its pipeline.
Amarantus Bioscience Holdings, Inc. (AMBS)
Developing therapeutic and diagnostic products for neurological disorders and orphan indications.
WE ARE PLEASED TO ANNOUNCE
AMARANTUS BIOSCIENCE HOLDINGS, INC.
AS A PRESENTING COMPANY AT THE MONACO GROWTH FORUM NOVEMBER 17th-18th
Amarantus Bioscience Holdings, Inc. (AMBS) was founded by a world-renewed molecular biologist and his Stanford University educated son to acquire and develop groundbreaking technologies in the biotechnology space. The management team has over 75 years of experience in the biotechnology sector in large pharmaceutical companies, small biotech companies, government and academic settings.
Amarantus Bioscience Holdings, Inc. (AMBS) will focus on developing unique technologies in the wound care/dermatology, neurology and ophthalmology sectors that address the critical unmet needs in each category. The technologies being developed all have clinical proof-of-concept and are being moved into mid-to-late stage clinical development on a path towards commercialization. The market opportunities in wound care/dermatology, neurology and ophthalmology represents $2B+, $4B+ and $2B+ respectively.
AMBS seeks to raise up to $30M US dollars to develop these assets through various stages of development.The funding can be focused on specific assets in special vehicles in order to participate in asset-centric valuation inflexion events. An acquisition of one or more of the assets by a larger pharmaceutical companies is the exit opportunity for institutional investors
AMBS’s objective is to develop these assets through further proof of concept in the next 12-24 months and divest the assets to larger companies in order to reinvest in its pipeline.
(0)
(0)
